相关实验视频

Updated: Apr 30, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

免疫检查点抑制剂治疗后骨矿物质密度的变化:从病例系列分析的见解

Vasiliki Siampanopoulou¹, Dimitrios C Ziogas², George Lyrarakis²

¹Endocrinology Unit, First Department of Medicine, Laiko General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

|August 10, 2025

概括

免疫检查点抑制剂 (ICI) 可能对癌症患者的骨矿物密度 (BMD) 产生负面影响. 那些患有骨质疏松症的人在一年的ICI治疗后经历了显著的BMD减少,突出了进一步研究的需要.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
骨的新陈代谢骨的新陈代谢

背景情况:

免疫检查点抑制剂 (ICI) 越来越多地用于癌症治疗.
越来越多的人对ICI的潜在骨副作用感兴趣,包括骨质疏松性骨折.
目前关于ICI对骨健康的影响的研究是有限的.

研究的目的:

研究一年免疫检查点抑制剂 (ICI) 治疗对瘤患者骨矿物质密度 (BMD) 和骨折发生的影响.
评估ICI对基线BMD水平不同患者骨健康的影响.

主要方法:

对15名癌症患者的双能X射线吸收仪 (DXA) 扫描进行了回顾性分析.
在ICI管理12个月的中位数之前和之后评估了BMD.
在随访期间,对骨质疏松性骨折的发生进行了监测.

主要成果:

患有基线骨质疏松症的患者显示,股骨 (6%) 和腰椎 (17.30%) BMD 显著减少.
患有正常基线BMD的患者经历了最小的变化 (0.15%的股骨,0.10%的腰骨).
患有骨质疏松症的患者没有显著的股骨 BMD 改变,并且腰部 BMD 略有减少 (0.07%).
在12个月的随访期间,在任何患者身上都没有观察到骨质疏松性骨折.

结论:

免疫检查点抑制剂 (ICI) 可能显著影响骨代谢,特别是在患有骨质疏松症的癌症患者中.
在ICI治疗一年后,正常的BMD或骨质疏松症患者没有表现出显著的BMD变化.
需要进行更大的前性研究来证实这些发现,并阐明ICI对骨健康的确切影响.

关键词:

不良事件是不良事件.骨的健康骨的健康骨矿物质密度骨矿物质密度免疫检查点抑制剂免疫检查点抑制剂骨质疏松症是一种骨质疏松症.

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.